Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Y mAbs Therapeutics
YMABCurrent price
11.59 USD
-1.3 USD (-10.09%)
Last closed
13.18 USD
Company
www.ymabs.com
ISIN
US9842411095
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
692 990 016 USD
Yield for 12 month
+120.76 %
1Y
3Y
5Y
10Y
15Y
YMAB
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. Address: 230 Park Avenue, New York, NY, United States, 10169
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
20.7 USDP/E ratio
–Dividend Yield
–Current Year
+84 819 000 USD
Last Year
+65 267 000 USD
Current Quarter
+18 461 000 USD
Last Quarter
+22 798 000 USD
Current Year
+73 403 000 USD
Last Year
+57 700 000 USD
Current Quarter
+18 461 000 USD
Last Quarter
+19 784 000 USD
Key Figures YMAB
1 year
3 years
5 years
10 years
EBITDA
-23 388 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-12 %
PEG Ratio
–
Return On Equity TTM
-24.78 %
Wall Street Target Price
20.7 USD
Revenue TTM
84 553 000 USD
Book Value
2.07 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-9.7 %
Dividend Yield
–
Gross Profit TTM
57 700 000 USD
Earnings per share
-0.56 USD
Diluted Eps TTM
-0.56 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-28.22 %
Dividend Analytics YMAB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History YMAB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation YMAB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
119.0476
Enterprise Value Revenue
7.0774
Price Sales TTM
8.1959
Enterprise Value EBITDA
-0.4309
Price Book MRQ
7.2276
Financials YMAB
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators YMAB
For 52 weeks
5.04 USD
20.9 USD
50 Day MA
14.11 USD
Shares Short Prior Month
4 170 638
200 Day MA
13.8 USD
Short Ratio
17.35
Shares Short
4 246 684
Short Percent
11.44 %
BeatStart